Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Diabetes, NASH & CVD Models
Are you facing unpredictable preclinical outcomes, high clinical trial failure rates, and poor translational validity in diabetes, NASH, or CVD drug development? Our NHP Metabolic Disease Models and Services help you maximize clinical predictability and de-risk IND submission through physiologically relevant disease modeling and advanced bioanalytical support.
Bridging the Translational Gap in Metabolic Disease Research with NHP Models!
Rodent models fall short in mimicking the intricate multi-organ pathophysiology of human metabolic and cardiovascular diseases, whereas NHP models deliver crucial translational data on efficacy, safety, and PK/PD closely aligned with human conditions.
Overview of NHP Applications
What Are Our Research Areas?
Metabolic diseases, including T2D, NASH, and CVD, are complex, interconnected syndromes that represent the leading causes of global morbidity and mortality. Preclinical research in these areas requires models that faithfully replicate the entire disease spectrum, from insulin resistance and dyslipidemia to organ damage (hepatic fibrosis, atherosclerosis, cardiomyopathy). Our NHP related services are designed to address this need by providing comprehensive support for drug and biologic development targeting these chronic conditions. We focus on models that naturally develop these pathologies, ensuring the test article's performance in the NHP is highly predictive of clinical outcomes.
Why Choose Us?
NHPs are the gold standard for metabolic disease research due to their profound physiological and genetic similarities to humans. Creative Biolabs leverages these advantages to accelerate your drug program:
- Genetic/Immunological Similarities: NHP genomes (e.g., macaque) are similar to the human genome. This ensures metabolic pathways, receptor pharmacology, and immune responses (e.g., cytokine profiles) are highly relevant to the human system, which is critical for complex, immune-mediated NASH and T2D.
- Clinical Translational Relevance: NHPs naturally develop adult-onset diseases like obesity, insulin resistance, dyslipidemia, and atherosclerosis over time, mirroring the human disease course—an advantage over most artificially induced rodent models.
- Complete Disease Pathophysiology: Unlike rodent models, the NHP system captures the complex, multi-organ crosstalk inherent to metabolic syndrome, allowing for the comprehensive study of the liver-pancreas-adipose-vascular axis.
Distributed under Unsplash License, from Unsplash.
Key Applications
NHPs provide the most physiologically accurate environment to investigate disease mechanisms and test the efficacy of novel drugs targeting metabolic and cardiovascular diseases.
- NASH & Liver Fibrosis: NHPs, such as the common marmoset, spontaneously develop a naturally occurring syndrome that accurately recapitulates the complete human NASH pathology, including steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis. This allows for the reliable testing of anti-fibrotic and anti-inflammatory agents and the evaluation of advanced therapies.
- T2D & Insulin Resistance: NHP models (e.g., rhesus macaques) naturally develop diet-induced obesity, insulin resistance and overt T2D. These models are ideal for assessing novel insulin sensitizers and other anti-diabetic compounds, including their impact on body weight and long-term glycemic control.
- CVD & Atherosclerosis: NHPs naturally develop human-like dyslipidemia and progressive atherosclerotic plaque formation in arterial beds. This makes them indispensable for assessing anti-dyslipidemic drugs and novel therapies targeting chronic inflammation and plaque stabilization.
- Maternal-Fetal Programming of Metabolic Disease: NHPs are the only reliable model to study the impact of maternal obesity and gestational diabetes on offspring health, providing critical insight into the developmental origins of health and disease and the intergenerational risk of metabolic syndrome.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides integrated service capabilities across the preclinical lifecycle, optimized for complex metabolic and cardiovascular studies. Explore our comprehensive services below:
| Service Capability | Corresponding Application Area |
| Metabolic Diseases Model Development | Assessing in vivo efficacy of drug candidates and advanced therapies in relevant disease models. |
| Single and Multiple-Dose PK Profiling | Evaluating drug exposure, metabolism, and correlation with efficacy biomarkers over time. |
| PK/TK Sample Analysis | Quantifying drug levels and tracking disease progression, target engagement, and immune response markers. |
| In Vivo Toxicology Studies | Establishing the safety profile of novel compounds, particularly liver, cardiac, and renal toxicity. |
Translational Impact
The inherent physiological and genetic alignment between NHPs and humans provides more reliable early proof of concept than is achievable with traditional models. This allows for the early detection of immune responses or organ toxicity (especially hepatic or cardiovascular damage) that may be missed in rodents. This proactive risk mitigation is invaluable. For NASH programs, having NHP data that confirms the reversal of human-relevant pathology can drastically reduce the risk of IND failure.
Frequently Asked Questions
Q: How do NHP metabolic disease models specifically improve the predictability of clinical trial outcomes?
A: NHP models develop the full spectrum of metabolic dysfunction naturally, which is highly consistent with human patients. This metabolic and immunological alignment means that drug candidates that perform well in the NHP model have a significantly higher predictive value for human efficacy and safety compared to genetically or artificially manipulated rodent models.
Q: What types of complex biomarkers or data can Creative Biolabs generate from NHP studies that I cannot get from rodents?
A: We provide advanced, multi-omics data specific to the primate system, including complex lipoprotein profiles, human-relevant cytokine/chemokine panels, and tissue-specific metabolomics. We can also perform advanced analyses like Flow Cytometry for immune cell profiling in key organs that reflect the systemic disease state.
Q: What is the typical turnaround time for a complete PK/PD study in a T2D NHP model?
A: The overall timeline for a full PK/PD study can vary widely based on the model chosen and the complexity of the analytical methods. However, Creative Biolabs provides an average turnaround time for bioanalysis and final integrated data reports of 4-8 weeks following the last sample collection. We are happy to provide a precise timeline based on your specific study design upon inquiry.
Contact Us
Creative Biolabs is your trusted partner for high-fidelity preclinical research in Diabetes, NASH, and CVD. We combine the gold-standard NHP model platform with comprehensive bioanalytical, PK/PD, and toxicology services to provide data with unmatched translational predictability. Contact Our Team for More Information and to Discuss Your Project